Whose Burden Is It Anyway? REMS’ Health Care Impact Belongs To FDA, PhRMA Says

Industry group contends that FDA should assess whether a REMS places an undue burden on the health care industry – because asking companies to do that evaluation would be an additional burden on the health care system.